TriFlo Cardiovascular develops the Tricuspid Flow Optimizer, a minimally invasive transcatheter device designed to treat tricuspid valve regurgitation in patients with varying valve sizes and anatomies. This solution addresses the limitations of traditional surgical interventions by providing a safe, durable, and customizable option that enhances patient outcomes without the need for high-risk surgery.
Funding
$15.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Tricuspid valve regurgitation (TR), a condition where blood flows backward in the heart, affects millions, particularly the elderly, leading to symptoms like fatigue and abdominal swelling. Current treatments, including drug therapy and surgery, have limitations, with surgery often posing high risks for many patients. This results in low treatment rates despite the severity and prevalence of symptomatic TR.
Solution
TriFlo Cardiovascular is developing the Tricuspid Flow Optimizer, a minimally invasive transcatheter device designed to treat tricuspid valve regurgitation. The device is designed to work with the native anatomy of the heart. Paired with the Optimizer is a transfemoral delivery system. The Optimizer aims to reduce regurgitation regardless of the size or shape of the native valve, potentially treating a wider range of patients.
Target Audience
The primary target audience includes elderly patients diagnosed with moderate to severe tricuspid regurgitation for whom traditional surgical interventions may be too risky.
Features
- Minimally invasive transfemoral delivery method for ease of implementation.
- Customizable intraoperatively to adapt to varying valve sizes and anatomies.
- Minimalistic design with secure fixation.
- Adaptive mini-valve with polymer leaflets for biocompatibility.
- Designed for scalability and favorable production processes.